** Traws Pharma's TRAW.O shares soar 129% to $11.30 premarket
** TRAW says its experimental bird flu drug, tivoxavir marboxil, was safe and well-tolerated in early-stage trial
** A single dose maintained levels of the drug in the blood for over 23 days in the trial, co says
** Mid-stage trial is expected to begin in H1 2025, co says
** Bird flu has infected more than 860 dairy herds in 16 U.S. states since March and killed 123 million poultry since the outbreak began in 2022
** As of last close, stock has fallen 73.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。